JP7212391B2 - ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途 - Google Patents

ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途 Download PDF

Info

Publication number
JP7212391B2
JP7212391B2 JP2020531764A JP2020531764A JP7212391B2 JP 7212391 B2 JP7212391 B2 JP 7212391B2 JP 2020531764 A JP2020531764 A JP 2020531764A JP 2020531764 A JP2020531764 A JP 2020531764A JP 7212391 B2 JP7212391 B2 JP 7212391B2
Authority
JP
Japan
Prior art keywords
antibody
igf1r
seq
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020531764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506770A (ja
Inventor
チヒョン アン，
ソンウォン アン，
ドンジン キム，
ウンシル スン，
ジェヒョン オン，
サンフン リー，
ウォンギョ ユ，
ジュヒ キム，
キョンジン パク，
ヘジン チョン，
ジノン ジュン，
ボラ リー，
ビョンジェ スン，
ヨンジュ キム，
ヨンギュ ソン，
セウォン アン，
テヘ ソン，
チソン ユ，
ヨントン パク，
トンフン ヨム，
ヨソプ リー，
ジェンホ ジュン，
Original Assignee
エービーエル バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エービーエル バイオ インコーポレイテッド filed Critical エービーエル バイオ インコーポレイテッド
Publication of JP2021506770A publication Critical patent/JP2021506770A/ja
Priority to JP2022059697A priority Critical patent/JP7513651B2/ja
Priority to JP2023000428A priority patent/JP2023052217A/ja
Application granted granted Critical
Publication of JP7212391B2 publication Critical patent/JP7212391B2/ja
Priority to JP2024061429A priority patent/JP7625305B2/ja
Priority to JP2024103513A priority patent/JP7806138B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020531764A 2017-12-14 2018-12-14 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途 Active JP7212391B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022059697A JP7513651B2 (ja) 2017-12-14 2022-03-31 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2023000428A JP2023052217A (ja) 2017-12-14 2023-01-05 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2024061429A JP7625305B2 (ja) 2017-12-14 2024-04-05 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2024103513A JP7806138B2 (ja) 2017-12-14 2024-06-27 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
KR10-2017-0172205 2017-12-14
KR20170172205 2017-12-14
US201862693474P 2018-07-03 2018-07-03
US62/693,474 2018-07-03
US201862734388P 2018-09-21 2018-09-21
US201862734391P 2018-09-21 2018-09-21
US62/734,388 2018-09-21
US62/734,391 2018-09-21
PCT/KR2018/015953 WO2019117684A1 (ko) 2017-12-14 2018-12-14 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022059697A Division JP7513651B2 (ja) 2017-12-14 2022-03-31 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2023000428A Division JP2023052217A (ja) 2017-12-14 2023-01-05 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途

Publications (2)

Publication Number Publication Date
JP2021506770A JP2021506770A (ja) 2021-02-22
JP7212391B2 true JP7212391B2 (ja) 2023-01-25

Family

ID=66819361

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2020531764A Active JP7212391B2 (ja) 2017-12-14 2018-12-14 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2022059697A Active JP7513651B2 (ja) 2017-12-14 2022-03-31 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2023000428A Withdrawn JP2023052217A (ja) 2017-12-14 2023-01-05 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2024061429A Active JP7625305B2 (ja) 2017-12-14 2024-04-05 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2024103513A Active JP7806138B2 (ja) 2017-12-14 2024-06-27 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022059697A Active JP7513651B2 (ja) 2017-12-14 2022-03-31 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2023000428A Withdrawn JP2023052217A (ja) 2017-12-14 2023-01-05 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2024061429A Active JP7625305B2 (ja) 2017-12-14 2024-04-05 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP2024103513A Active JP7806138B2 (ja) 2017-12-14 2024-06-27 ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途

Country Status (9)

Country Link
US (2) US12071483B1 (https=)
EP (2) EP3725806A4 (https=)
JP (5) JP7212391B2 (https=)
KR (1) KR102263812B1 (https=)
CN (2) CN111886251A (https=)
AU (2) AU2018385230B2 (https=)
BR (1) BR112020011875A2 (https=)
CA (1) CA3085572A1 (https=)
WO (2) WO2019117685A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
KR102508933B1 (ko) * 2017-11-17 2023-03-13 에이비엘바이오 주식회사 알파-시누클레인에 대한 항체 및 그 용도
EP3725806A4 (en) * 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
US12473342B2 (en) * 2018-04-27 2025-11-18 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
EP4268842A3 (en) * 2019-06-14 2024-05-22 ABL Bio, Inc. BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF
CA3163017A1 (en) * 2019-12-26 2021-07-01 Daehae SONG Method for purifying biologically active peptide by using protein a affinity chromatography
US20250304709A1 (en) * 2022-05-05 2025-10-02 Eli Lilly And Company Multispecific binding molecules and methods of use thereof
WO2026029176A1 (ja) * 2024-08-01 2026-02-05 株式会社抗体医学研究所 抗インテグリンα８β１抗体
CN118805740B (zh) * 2024-08-07 2025-12-19 中国中医科学院中药研究所 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015232002A (ja) 2011-10-28 2015-12-24 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
JP2016511254A (ja) 2013-02-28 2016-04-14 ユナイテッド アラブ エミレーツ ユニバーシティＵｎｉｔｅｄ Ａｒａｂ Ｅｍｉｒａｔｅｓ Ｕｎｉｖｅｒｓｉｔｙ アルファ−シヌクレイン抗体及びその使用
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
JP2017512464A (ja) 2014-03-06 2017-05-25 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP2017513461A (ja) 2014-03-06 2017-06-01 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP2017514456A (ja) 2014-03-06 2017-06-08 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
DE602004029581D1 (de) 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
CN102164960A (zh) * 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
CN102307935B (zh) 2008-12-23 2017-06-09 3M创新有限公司 无定形微孔有机硅酸盐组合物
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
BR112014010664A2 (pt) 2011-11-02 2017-04-25 Biogen Idec Int Neuroscience Gmbh uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro
DK2807188T3 (da) * 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
HUE045144T2 (hu) 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2906596B1 (en) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
KR20140138533A (ko) * 2013-05-24 2014-12-04 한화케미칼 주식회사 항 igf-1r 단일클론 항체 및 이를 포함하는 암치료용 조성물
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
KR101906558B1 (ko) * 2014-02-28 2018-10-11 (재) 스크립스코리아항체연구원 Tspan8에 특이적인 신규 항체 및 이의 용도
CA2944402A1 (en) * 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
EP3567054A4 (en) 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
EP3661961A4 (en) 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
KR102508933B1 (ko) 2017-11-17 2023-03-13 에이비엘바이오 주식회사 알파-시누클레인에 대한 항체 및 그 용도
EP3725806A4 (en) 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
EP4268842A3 (en) 2019-06-14 2024-05-22 ABL Bio, Inc. BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF
TW202309076A (zh) 2021-05-12 2023-03-01 南韓商Ａｂｌ生物公司 用於治療α-突觸核蛋白病之抗體

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015232002A (ja) 2011-10-28 2015-12-24 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
JP2016511254A (ja) 2013-02-28 2016-04-14 ユナイテッド アラブ エミレーツ ユニバーシティＵｎｉｔｅｄ Ａｒａｂ Ｅｍｉｒａｔｅｓ Ｕｎｉｖｅｒｓｉｔｙ アルファ−シヌクレイン抗体及びその使用
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
JP2017512464A (ja) 2014-03-06 2017-05-25 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP2017513461A (ja) 2014-03-06 2017-06-01 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP2017514456A (ja) 2014-03-06 2017-06-08 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法

Also Published As

Publication number Publication date
JP2024096805A (ja) 2024-07-17
AU2022241522A1 (en) 2022-12-22
KR20200067838A (ko) 2020-06-12
JP2022104966A (ja) 2022-07-12
KR102263812B1 (ko) 2021-06-14
EP3725806A1 (en) 2020-10-21
JP2021506770A (ja) 2021-02-22
JP7806138B2 (ja) 2026-01-26
WO2019117684A1 (ko) 2019-06-20
EP4403218A2 (en) 2024-07-24
JP2023052217A (ja) 2023-04-11
CN116731173A (zh) 2023-09-12
CN111886251A (zh) 2020-11-03
EP4403218A3 (en) 2024-11-06
JP7513651B2 (ja) 2024-07-09
AU2022241522B2 (en) 2025-02-20
AU2018385230A1 (en) 2020-07-02
EP3725806A4 (en) 2022-03-30
CA3085572A1 (en) 2019-06-20
WO2019117685A3 (ko) 2019-08-01
US20240101687A1 (en) 2024-03-28
US12071483B1 (en) 2024-08-27
JP2024156657A (ja) 2024-11-06
JP7625305B2 (ja) 2025-02-03
AU2018385230B2 (en) 2022-10-13
WO2019117685A2 (ko) 2019-06-20
BR112020011875A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
JP7625305B2 (ja) ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
JP7710000B2 (ja) α－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
EA047717B1 (ru) БИСПЕЦИФИЧНОЕ АНТИТЕЛО К α-SYN/IGF1R И ЕГО ПРИМЕНЕНИЕ
EA045348B1 (ru) БИСПЕЦИФИЧНОЕ АНТИТЕЛО К α-SYN/IGF1R И ЕГО ПРИМЕНЕНИЕ
HK40073718A (en) Bispecific antibody against a-syn/igf1r and use thereof
HK40032661A (en) Bispecific antibody to a-syn/igf1r and use thereof
BR122025025877A2 (pt) ANTICORPO BISPECÍFICO AO alfa-SYN/IGF1R E USO DO MESMO
EA047682B1 (ru) БИСПЕЦИФИЧЕСКОЕ АНТИТЕЛО К α-SYN/IGF1R И ЕГО ПРИМЕНЕНИЕ
EA050076B1 (ru) Антитело к igf1r и его применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20200811

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230105

R150 Certificate of patent or registration of utility model

Ref document number: 7212391

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250